COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

NCL Leadership Changes

The NCL is proud to announce the appointment of Drs. Marina Dobrovolskaia and Stephan Stern as Laboratory Co-Directors. Dr. Dobrovolskaia will serve as Director of Operations for the lab, and Dr. Stern will serve as Director of Research & Development for the lab.

NCL will continue to support nanotech developers in their translational efforts by offering characterization and formulation services through mechanisms such as NCL’s Assay Cascade, cCRADA and TSA. In addition to their new roles, Dr. Dobrovolskaia will continue to lead NCL’s Immunology Section, and Dr. Stern will continue to lead NCL’s Pharmacology, Toxicology and Formulations Sections. Rounding out the NCL’s leadership team, Dr. Jeffrey Clogston will continue to lead NCL’s Physicochemical Characterization Section, and Dr. Rachael Crist will be NCL’s Head of Strategic Client Relations. 

These exciting new leadership changes will help advance the NCL’s key strategic goals in supporting the missions of the Frederick National Laboratory for Cancer Research and the National Cancer Institute. And, as always, our mission remains to help promote the translation of novel nanotech concepts to clinical trials.

We look forward to continuing to serve the nanotech community!